Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Category: #health  By Nikita Chaurasia  Date: 2020-03-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC.

In a poster session that was showcased by Harold E Bays, FOMA, MD, FTOS, FACE, FTOS, FNLA, FACC., it was highlighted that in Phase 2 trial, NEXLIZET lowered LDL-C significantly by a 40% mean as compared placebo, lowered hsCRP by 25% in comparison to the baseline, and further did not worsen glycemic control.

Along with the first poster, an additional poster session was conducted by Eric S. G. Stroes, MD., PhD. This poster signified that inside the pooled Phase 3 trials, NEXLETOL substantially decreased hsCRP in patients suffering from hypercholesterolemia irrespective of the intensity or presence of background statin treatment.

The third and final poster session was conducted by Maciej Banach, Ph.D., FESC, FAHA, MD. In the session it was highlighted that in Phase 3, NEXLETOL facilitated significant additional lowering of LDL-C while also significantly lowering other lipid endpoints, irrespective of background ezetimibe presence. Most notably, NEXLETOL’s safety profile was similar without or with background ezetimibe treatment.

Tim Mayleben, President and the Chief Executive Officer of Esperion stated that the company is thrilled with the final outcomes of Phase 2 trials that signifies NEXLIZET gained a 40 percent LDL-C lowering, a substantial 25 percent decrease in hsCRP and did not exacerbate glycemic control in patients suffering from Type 2 diabetes. The pooled analyses from Phase 3 LDL-C decreasing development program shows that NEXLETOL can be safely integrated with multiple LDL-C medicines, crucial to aid more patients to achieve their LDL-C objectives.

Mayleben further added that these analyses assure the safety and efficacy of the company’s medicines for millions of patients wanting to decrease their bad cholesterol levels.

 

Source credit: https://www.esperion.com/investors-media/press-releases/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

One in three UK firms to cut jobs by third quarter of 2020, poll finds
One in three UK firms to cut jobs by third quarter of 2020, poll finds
By Nikita Chaurasia

According to a recent study regarding the economic impact of COVID-19, one in three employers in the United Kingdom are predicted to cut jobs by the third quarter of 2020. Sources close to the matter stated that the survey included over 33% of 2,000 ...

Equinix acquires Premier Partner status with Google Cloud Platform
Equinix acquires Premier Partner status with Google Cloud Platform
By Nikita Chaurasia

America-based multinational data center giant Equinix Inc., has reportedly acquired premier partner status by extending its relations with Google Cloud platform. Sources with relevant information stated that the recent development will allow the two ...

Uber, Lyft sued for alleged wage theft by California labor commissioner
Uber, Lyft sued for alleged wage theft by California labor commissioner
By Nikita Chaurasia

America-based ride sharing companies Uber Technologies Inc. and Lyft Inc. have been reportedly sued over alleged wage theft by California labor commissioner. According to the lawsuit, the classification of drivers as freelancers have not only violat...